Prospective Grant of Exclusive License: Inhibitors of the Plasmodial Surface Anion Channel as Antimalarials, 2130 [2011-549]

Download as PDF 2130 Federal Register / Vol. 76, No. 8 / Wednesday, January 12, 2011 / Notices campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver’s license, or passport) and to state the purpose of their visit. Information is also available on the Institute’s/Center’s home page: https:// www.ninds.nih.gov, where and agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS) Dated: January 5, 2011. Jennifer S. Spaeth, Director, Office of Federal Advisory Committee Policy. BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive License: Inhibitors of the Plasmodial Surface Anion Channel as Antimalarials National Institutes of Health, Public Health Service, HHS. ACTION: Notice. AGENCY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in U.S. Provisional Patent Application No. 61/083,000, filed July 23, 2008 [HHS Ref. No. E–202–2008/0– US–01], now expired and PCT Patent Application No. PCT/US09/50637 [HHS Ref. No. E–202–2008/0–PCT–02] filed July 15, 2009, which published as WO/ 2010/011537 on January 28, 2010, both applications entitled ‘‘Inhibitors of the Plasmodial Surface Anion Channel As Antimalarials,’’ and all continuing applications and foreign counterparts to Microbiotix, Inc., having a place of business in Worcester, Massachusetts. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license territory may be ‘‘worldwide’’, and the field of use may be limited to ‘‘prevention and treatment of malaria in humans.’’ DATES: Only written comments and/or applications for a license which are received by the NIH Office of mstockstill on DSKH9S0YB1PROD with NOTICES VerDate Mar<15>2010 17:25 Jan 11, 2011 Jkt 223001 DEPARTMENT OF HOMELAND SECURITY Requests for copies of the patent application, inquiries, comments, and other materials relating to the contemplated exclusive license should be directed to: Kevin W. Chang, PhD, Senior Licensing and Patenting Manager, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 435–5018; Facsimile: (301) 402– 0220; E-mail: changke@mail.nih.gov. Office of the Secretary ADDRESSES: The subject technologies are antimalarial small molecule inhibitors of the plasmodial surface anion channel (PSAC), an essential nutrient acquisition ion channel expressed on human erythrocytes infected with malaria parasites. These inhibitors were discovered by high-throughput screening of chemical libraries and analysis of their ability to kill malaria parasites in culture. Two separate classes of inhibitors were found to work synergistically in combination against PSAC and killed malaria cultures at markedly lower concentrations than separately. These inhibitors have high affinity and specificity for PSAC and have acceptable cytotoxicity profiles. The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within thirty (30) days from the date of this published notice, the NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. SUPPLEMENTARY INFORMATION: [FR Doc. 2011–577 Filed 1–11–11; 8:45 am] SUMMARY: Technology Transfer on or before February 11, 2011 will be considered. Dated: January 6, 2011. Richard U. Rodriguez, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. 2011–549 Filed 1–11–11; 8:45 am] BILLING CODE 4140–01–P PO 00000 Frm 00050 Fmt 4703 Sfmt 4703 Exercise of Authority Under Section 212(d)(3)(B)(i) of the Immigration and Nationality Act Office of the Secretary, DHS. Notice of determination. AGENCY: ACTION: Authority: 8 U.S.C. 1182(d)(3)(B)(i). Following consultations with the Secretary of State and the Attorney General, I hereby conclude, as a matter of discretion in accordance with the authority granted to me by section 212(d)(3)(B)(i) of the Immigration and Nationality Act (INA), 8 U.S.C. 1182(d)(3)(B)(i), as amended, as well as the foreign policy and national security interests deemed relevant in these consultations, that subsection 212(a)(3)(B)(iv)(VI) of the INA, 8 U.S.C. 1182(a)(3)(B)(iv)(VI), shall not apply, with respect to an alien, for the provision of material support to the All India Sikh Students Federation-Bittu Faction, provided that the alien satisfies the relevant agency authority that the alien: (a) Is seeking a benefit or protection under the INA and has been determined to be otherwise eligible for the benefit or protection; (b) Has undergone and passed all relevant background and security checks; (c) Has fully disclosed, to the best of his or her knowledge, in all relevant applications and interviews with U.S. government representatives and agents, the nature and circumstances of each provision of material support and any other activity or association falling within the scope of section 212(a)(3)(B) of the INA, 8 U.S.C. 1182(a)(3)(B); (d) Has not participated in, or knowingly provided material support to, terrorist activities that targeted noncombatant persons or U.S. interests; (e) Poses no danger to the safety and security of the United States; and (f) Warrants an exemption from the relevant inadmissibility provision in the totality of the circumstances. Implementation of this determination will be made by U.S. Citizenship and Immigration Services (USCIS), in consultation with U.S. Immigration and Customs Enforcement (ICE), or by U.S. consular officers, as applicable, who shall ascertain, to their satisfaction, and in their discretion, that the particular applicant meets each of the criteria set forth above. This exercise of authority may be revoked as a matter of discretion and E:\FR\FM\12JAN1.SGM 12JAN1

Agencies

[Federal Register Volume 76, Number 8 (Wednesday, January 12, 2011)]
[Notices]
[Page 2130]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-549]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Inhibitors of the 
Plasmodial Surface Anion Channel as Antimalarials

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health, Department 
of Health and Human Services, is contemplating the grant of an 
exclusive patent license to practice the inventions embodied in U.S. 
Provisional Patent Application No. 61/083,000, filed July 23, 2008 [HHS 
Ref. No. E-202-2008/0-US-01], now expired and PCT Patent Application 
No. PCT/US09/50637 [HHS Ref. No. E-202-2008/0-PCT-02] filed July 15, 
2009, which published as WO/2010/011537 on January 28, 2010, both 
applications entitled ``Inhibitors of the Plasmodial Surface Anion 
Channel As Antimalarials,'' and all continuing applications and foreign 
counterparts to Microbiotix, Inc., having a place of business in 
Worcester, Massachusetts. The patent rights in these inventions have 
been assigned to the United States of America.
    The prospective exclusive license territory may be ``worldwide'', 
and the field of use may be limited to ``prevention and treatment of 
malaria in humans.''

DATES: Only written comments and/or applications for a license which 
are received by the NIH Office of Technology Transfer on or before 
February 11, 2011 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
comments, and other materials relating to the contemplated exclusive 
license should be directed to: Kevin W. Chang, PhD, Senior Licensing 
and Patenting Manager, Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
MD 20852-3804; Telephone: (301) 435-5018; Facsimile: (301) 402-0220; E-
mail: changke@mail.nih.gov.

SUPPLEMENTARY INFORMATION: The subject technologies are antimalarial 
small molecule inhibitors of the plasmodial surface anion channel 
(PSAC), an essential nutrient acquisition ion channel expressed on 
human erythrocytes infected with malaria parasites. These inhibitors 
were discovered by high-throughput screening of chemical libraries and 
analysis of their ability to kill malaria parasites in culture. Two 
separate classes of inhibitors were found to work synergistically in 
combination against PSAC and killed malaria cultures at markedly lower 
concentrations than separately. These inhibitors have high affinity and 
specificity for PSAC and have acceptable cytotoxicity profiles.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless within thirty 
(30) days from the date of this published notice, the NIH receives 
written evidence and argument that establishes that the grant of the 
license would not be consistent with the requirements of 35 U.S.C. 209 
and 37 CFR 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: January 6, 2011.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 2011-549 Filed 1-11-11; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.